# Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

> **NCT04614987** · — · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 17 (actual)

## Conditions studied

- Neurotoxicity

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04614987
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-25
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-09-13
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** PI decided to close study early.
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04614987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04614987, "Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04614987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*